School of Science, Engineering & Environment

FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity (2023)
Journal Article
Fiorillo, M., Ricci, E., Fava, M., Longobucco, C., Sotgia, F., Rizza, P., …Sisci, D. (in press). FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity. Cells, 12(24), 2777. https://doi.org/10.3390/cells12242777

Tamoxifen-resistant breast cancer cells (TamR-BCCs) are characterized by an enhanced metabolic phenotype compared to tamoxifen-sensitive cells. FoxO3a is an important modulator of cell metabolism, and its deregulation has been involved in the acquisi... Read More about FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity.

Antibiotics that target mitochondria extend lifespan in C. elegans (2023)
Journal Article
Bonuccelli, G., Brooks, D. R., Shepherd, S., Sotgia, F., Lisanti, M. P., Brooks, D. R., & Lisanti, M. P. (in press). Antibiotics that target mitochondria extend lifespan in C. elegans. Aging, 15(21), 11764-11781. https://doi.org/10.18632/aging.205229

Aging is a continuous degenerative process caused by a progressive decline of cell and tissue functions in an organism. It is induced by the accumulation of damage that affects normal cellular processes, ultimately leading to cell death. It has been... Read More about Antibiotics that target mitochondria extend lifespan in C. elegans.

SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production (2022)
Journal Article
Mauro Lizcano, M., Sotgia, F., & Lisanti, M. (2022). SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production. Aging, 14(24), 9877-9889. https://doi.org/10.18632/aging.204452

Cancer stem cells (CSCs) are responsible for cancer recurrence, treatment failure and metastatic dissemination. As such, the elimination of CSCs represents one of the most important approaches for the future of cancer treatment. Among other propertie... Read More about SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production.

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation (2022)
Journal Article
Bonuccelli, G., Sotgia, F., & Lisanti, M. (2022). Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation. Aging, 14(23), 9466-9483. https://doi.org/10.18632/aging.204412

Here, we report the identification of key compounds that effectively inhibit the anchorage-independent growth and propagation of cancer stem cells (CSCs), as determined via screening using MCF7 cells, a human breast adenocarcinoma cell line. More spe... Read More about Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation.

New insights into cholesterol-mediated ERRα activation in breast cancer progression and pro-tumoral microenvironment orchestration. (2022)
Journal Article
Brindisi, M., Frattaruolo, L., Fiorillo, M., Dolce, V., Sotgia, F., Lisanti, M., & Cappello, A. (2022). New insights into cholesterol-mediated ERRα activation in breast cancer progression and pro-tumoral microenvironment orchestration. FEBS Journal, https://doi.org/10.1111/febs.16651

Breast cancer remains the greatest cause of cancer-related death in women worldwide. Its aggressiveness and progression derive from intricate processes that occur simultaneously both within the tumour itself and in the neighbouring cells that make up... Read More about New insights into cholesterol-mediated ERRα activation in breast cancer progression and pro-tumoral microenvironment orchestration..

Investigating senescence and senescence-escape in cancer cells (2022)
Thesis
Toth, F. (2022). Investigating senescence and senescence-escape in cancer cells. (Thesis). University of Salford

Despite the general concept that therapy-induced senescence (TIS) has a tumour-suppressive role, the presence of senescent tumour cells and the ability of cancer cells to escape from senescence could potentially lead to therapy resistance and tumour... Read More about Investigating senescence and senescence-escape in cancer cells.

High ATP production fuels cancer drug resistance and metastasis : implications for mitochondrial ATP depletion therapy (2021)
Journal Article
Fiorillo, M., Ozsvari, B., Sotgia, F., & Lisanti, M. (2021). High ATP production fuels cancer drug resistance and metastasis : implications for mitochondrial ATP depletion therapy. Frontiers in Oncology, 11, 740720. https://doi.org/10.3389/fonc.2021.740720

Recently, we presented evidence that high mitochondrial ATP production is a new therapeutic target for cancer treatment. Using ATP as a biomarker, we isolated the “metabolically fittest” cancer cells from the total cell population. Importantly, ATP-h... Read More about High ATP production fuels cancer drug resistance and metastasis : implications for mitochondrial ATP depletion therapy.

MitoTracker Deep Red (MTDR) is a metabolic inhibitor for targeting mitochondria and eradicating cancer stem cells (CSCs), with anti-tumor and anti-metastatic activity in vivo (2021)
Journal Article
Sargiacomo, C., Stonehouse, S., Moftakhar, Z., Sotgia, F., & Lisanti, M. (2021). MitoTracker Deep Red (MTDR) is a metabolic inhibitor for targeting mitochondria and eradicating cancer stem cells (CSCs), with anti-tumor and anti-metastatic activity in vivo. Frontiers in Oncology, 11, 678343. https://doi.org/10.3389/fonc.2021.678343

MitoTracker Deep Red (MTDR) is a relatively non-toxic, carbocyanine-based, far-red, fluorescent probe that is routinely used to chemically mark and visualize mitochondria in living cells. Previously, we used MTDR at low nano-molar concentrations to... Read More about MitoTracker Deep Red (MTDR) is a metabolic inhibitor for targeting mitochondria and eradicating cancer stem cells (CSCs), with anti-tumor and anti-metastatic activity in vivo.

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase (2021)
Journal Article
Fiorillo, M., Scatena, C., Naccarato, A., Sotgia, F., & Lisanti, M. (2021). Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell Death and Differentiation, 28(9), 2797-2817. https://doi.org/10.1038/s41418-021-00788-x

Here, we provide evidence that high ATP production by the mitochondrial ATP-synthase is a new therapeutic target for anticancer therapy, especially for preventing tumor progression. More specifically, we isolated a subpopulation of ATP-high cancer ce... Read More about Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase.

Outputs (71)